ArticleBMC pulmonary medicine2026
Prognostic significance of nodal subclassification and adjuvant therapy in surgically treated T1-4N1-2M0 non-small cell lung cancer: a single-center retrospective study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the prognostic significance of nodal subclassification in surgically treated patients with non-small cell lung cancer who had pathological N1-N2 disease, based on the ninth edition of the Tumor-Node-Metastasis classification.
methodsAll patients with pathologically confirmed stage T1-4N1-2M0 non-small cell lung cancer who underwent anatomical lung resection with systematic mediastinal lymph node dissection were retrospectively reviewed. Patients who received preoperative therapy or had incomplete resections were excluded. Nodal involvement was classified as pathological N1, N2a, and N2b; N2 cases were divided into N2a1, N2a2, N2b1, and N2b2 according to skip and station status. In addition, single-zone and multi-zone metastases were evaluated to investigate the spatial distribution of mediastinal spread. Overall and recurrence-free survival were analyzed using Kaplan-Meier and multivariable Cox regression methods.
resultsThe median overall survival was 45, 30, and 19 months for the pathological N1, N2a, and N2b groups, respectively. Patients in the N2a2 subgroup demonstrated the most favorable survival, whereas those in the N2b2 subgroup had the poorest outcomes. Skip metastasis was not associated with any survival benefit, while multi-station and multi-zone involvement were related to worse long-term results. In multivariable analysis, multiple-station disease and postoperative complications were independent adverse factors, whereas younger age and administration of adjuvant chemotherapy were independently associated with improved survival.
conclusionThe ninth edition of the Tumor-Node-Metastasis classification provides a more accurate prognostic stratification for surgically treated patients with pathological N2 disease. Multi-station and multi-zone metastases represent more aggressive patterns, while carefully selected single-station N2a2 cases can achieve survival similar to N1 disease, supporting the clinical usefulness of refined nodal and zone-based subclassification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.